Who is sponsoring NCT05187819?

NCT05187819 is sponsored by Helse Stavanger HF.

What drugs are being tested in NCT05187819?

Interventions in NCT05187819: predictive value of a blood test.

What condition does NCT05187819 study?

NCT05187819 studies Dementia Alzheimers.

Is NCT05187819 still recruiting?

NCT05187819 is currently recruiting now. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT05187819

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blood-based Biomarkers for Diagnosis of Alzheimer's

Recruiting now NA Last updated 28 September 2023

What this trial tests

NA trial testing predictive value of a blood test in Dementia Alzheimers in 300 participants. Currently enrolling.

Timeline

1 June 2023

Primary endpoint
31 December 2026

31 December 2029

Quick facts

Lead sponsor	Helse Stavanger HF
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	diagnostic
Enrollment	300
Start date	1 June 2023
Primary completion	31 December 2026
Estimated completion	31 December 2029
Sites	1 location across Norway

Drugs / interventions tested

predictive value of a blood test

Conditions studied

Dementia Alzheimers — all drugs for Dementia Alzheimers →

Sponsor

Helse Stavanger HF — full company profile →

Who can join

Adults 40 to 100, any sex, with Dementia Alzheimers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests have a reliable ability to differentiate AD from other neurodegenerative disorders and identify AD across the clinical continuum with high sensitivity and specificity in research cohorts with a high prevalence of AD. This project will assess the predictive value of these tests in a general practice population. The hypothesis is that the actual blood panel will have high positive predictive value for a diagnosis of Alzheimer's disease in the primary health care setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Dementia Alzheimers

Currently open trials in the same condition.

NCT06631144 — A Spanish-language Caregiver-Enabled Care Program · NA · active not recruiting
NCT06704971 — Assessing Cognitive Decline at Home · recruiting
NCT06508268 — Language, Speech and Motor Function in MCI Due to AD and Alzheimer's Disease · recruiting
NCT06993207 — HOme-based Brain Monitoring With a GARment-EEG to Study Cognitive Decline in the Aging Population · recruiting
NCT05529277 — Implementing Dementia Care Management Into Routine Care in the Region Siegen-Wittgenstein · active not recruiting

Other Helse Stavanger HF trials

Trials by the same sponsor.

NCT06983002 — Bridging Affect Consciousness, Mentalization and Trauma- Exploring an Integrative Treatment Approach for Personality Dis · NA · not yet recruiting
NCT06774261 — Phenserine on the Alzheimer's Treatment Horizon, Study 1 · Phase 1 · not yet recruiting
NCT06362707 — Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD) · Phase 2 · recruiting
NCT06211907 — Small Macular Holes Treated With Air · NA · recruiting
NCT06150274 — Comparison of Wire Assisted Percutaneous Balloon Mitral Valvulotomy With Standard Inoue Balloon Valvulotomy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05187819 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Helse Stavanger HF
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05187819.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing